Generic Name and Formulations:
Fluticasone propionate 93mcg/spray; aqueous nasal spray.
OptiNose US, Inc.
RECENT UPDATESMonograph added.
Indications for XHANCE:
≥18yrs: 1 spray in each nostril twice daily. Also, 2 sprays in each nostril twice daily may be effective in some patients. Max total daily doses: 2 sprays in each nostril twice daily (744mcg/day).
<18yrs: not established.
Maintain regular regimen. Do not exceed recommended dose. Respiratory tract tuberculosis. Systemic infections. Ocular herpes simplex. Immunosuppression. If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, lassitude, depression). Recent nasal ulceration, surgery, trauma; avoid until healing has occurred. Change in vision, history of increased intraocular pressure, glaucoma, and/or cataracts; monitor closely. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and candida infection or other nasal mucosal changes. Discontinue if septal perforation occurs. Discontinue if hypersensitivity reactions occur. Prolonged immobilization, family history of osteoporosis, postmenopausal, tobacco use, advanced age, poor nutrition: monitor bone mineral density. Hepatic impairment: monitor. Pregnancy. Nursing mothers.
Concomitant strong CYP3A4 inhibitors (eg, ritonavir, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, saquinavir, ketoconazole, telithromycin, conivaptan, lopinavir, voriconazole): not recommended. Additive effects with chronic use of drugs that can reduce bone mineral density (eg, anticonvulsants, oral corticosteroids): monitor.
Epistaxis, nasal septal ulceration/erythema, nasopharyngitis, nasal mucosal erythema/ulcerations, nasal congestion, acute sinusitis, headache, pharyngitis; impaired wound healing, reduced bone mineral density, HPA axis effects, reduced growth velocity in children.
Spray—16mL (120 sprays)
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- #MeToo: Helping Victims Cope With Sexual Harassment
- Association Between Psychosis and Development of Dementia in Older Men
- Phonemic Verbal Advantage in Mild Cognitive Impairment May Predict Risk for Alzheimer Disease
- Psychosis Could Be a Potential Side Effect of Steroid Treatment in Kids
- Guidance Offered for Improving Mental Health in Workplace
- Triiodothyronine in the Treatment of Bipolar Depression
- Nutritional Influences on Bipolar Disorder in Children
- Old Challenges and New Directions in Managing Tardive Dyskinesia
- Early Intervention Strategies for Bipolar Disorder: Clinical Dilemmas and Directions
- Similar Rates of Childhood Trauma in Schizophrenia and Substance Use Disorders
- Bully for Us: Confronting Medicine's Bullying Problem
- Personality Functioning Associated With Global Functioning in Bipolar Disorder I
- Higher Incidence of Mania in Adults With Intellectual Disabilities vs General Population
- Youth With Gender Nonconformity Vulnerable to Adversity
- Negative Affect That Lingers Tied to Health 10 Years Later